ESTRELLA IMMUNOPHARMA, INC. Stock-Based Compensation
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Stock-Based Compensation of $145.30 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $145.30K, a 8.67% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $146.71K, a 7.78% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $148.36K.
- ESTRELLA IMMUNOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $152.42K.
- ESTRELLA IMMUNOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $618.97K.
- ESTRELLA IMMUNOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $1.19M, a 191.67% increase from fiscal 2023.
- ESTRELLA IMMUNOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $409.60K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $145.30K 10-Q · filed 2026-08-13 | $292.01K 10-Q · filed 2026-08-13 | $440.37K derived: sum of 3 quarters · filed 2026-08-13 | $592.79K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $146.71K 10-Q · filed 2026-05-18 | $295.07K derived: sum of 2 quarters · filed 2026-05-18 | $447.50K derived: sum of 3 quarters · filed 2026-05-18 | $606.59K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $148.36K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $300.78K derived: sum of 2 quarters · filed 2026-03-18 | $459.88K derived: sum of 3 quarters · filed 2026-08-13 | $618.97K 10-K · filed 2026-03-18 |
| 2025-09-30 | $152.42K 10-Q · filed 2025-11-12 | $311.52K derived: sum of 2 quarters · filed 2026-08-13 | $470.61K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $159.10K 10-Q · filed 2026-08-13 | $318.19K 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $159.09K 10-Q · filed 2026-05-18 | |||
| 2024-12-31 | $432.26K 10-K · filed 2026-03-18 | |||
| 2024-06-30 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 derived: sum of 3 quarters · filed 2025-03-25 | $1.19M 10-KT · filed 2025-03-25 |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2024-05-15 | $1.19M 10-Q · filed 2024-05-15 | $1.30M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $1.19M 10-Q · filed 2024-02-14 | $1.30M derived: sum of 3 quarters · filed 2024-11-14 | $1.40M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-09-30 | $1.19M 10-Q · filed 2024-11-14 | $1.30M derived: sum of 2 quarters · filed 2024-11-14 | $1.40M derived: sum of 3 quarters · filed 2024-11-14 | $1.50M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $102.40K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-27 | $204.80K derived: sum of 2 quarters · filed 2024-09-27 | $307.20K derived: sum of 3 quarters · filed 2024-09-27 | $409.60K 10-K · filed 2024-09-27 |
| 2023-03-31 | $102.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $204.80K derived: sum of 2 quarters · filed 2024-05-15 | $307.20K 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $102.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $204.80K 10-Q · filed 2024-02-14 | ||
| 2022-09-30 | $102.40K 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |